These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
539 related articles for article (PubMed ID: 29532519)
21. Comprehensive review of glucagon-like peptide 1 receptor agonist treatment on the risk of cardiovascular outcomes and retinopathy as diabetic complications. Liu H; Zhang JT; Xin SH; Ren WN; Lu QK Eur Rev Med Pharmacol Sci; 2023 Mar; 27(6):2332-2340. PubMed ID: 37013752 [TBL] [Abstract][Full Text] [Related]
22. Glucose-Lowering Medications and Cardiovascular Outcomes. Shanmugasundaram M; Pineda JRE; Murugapandian S Curr Cardiol Rep; 2021 Mar; 23(4):24. PubMed ID: 33655453 [TBL] [Abstract][Full Text] [Related]
23. The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism. Pan X; Xu S; Li J; Tong N Front Endocrinol (Lausanne); 2020; 11():599355. PubMed ID: 33335511 [TBL] [Abstract][Full Text] [Related]
24. DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People With Cardiovascular Disease. Sonoda K; Saguil A Am Fam Physician; 2022 Jul; 106(1):24-25. PubMed ID: 35839371 [No Abstract] [Full Text] [Related]
25. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197 [TBL] [Abstract][Full Text] [Related]
26. Type 2 Diabetes Medication and Cardiovascular Benefits. Shrestha A; Munankarmi R S D Med; 2021 Mar; 74(3):132-135. PubMed ID: 34232594 [TBL] [Abstract][Full Text] [Related]
27. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. North EJ; Newman JD Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559 [TBL] [Abstract][Full Text] [Related]
28. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade. Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199 [TBL] [Abstract][Full Text] [Related]
29. Opportunities of Antidiabetic Drugs in Cardiovascular Medicine: A Meta-Analysis and Perspectives for Trial Design. Yan C; Thijs L; Cao Y; Trenson S; Zhang ZY; Janssens S; Staessen JA; Feng YM Hypertension; 2020 Aug; 76(2):420-431. PubMed ID: 32639887 [TBL] [Abstract][Full Text] [Related]
30. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors. McReelis KD; Lovshin JA Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013 [No Abstract] [Full Text] [Related]
32. [Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes]. Scheen AJ Rev Med Suisse; 2019 Aug; 15(659):1436-1441. PubMed ID: 31436058 [TBL] [Abstract][Full Text] [Related]
33. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus. Sharma A; Verma S Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322 [TBL] [Abstract][Full Text] [Related]
34. New Glucose-Lowering Agents for Diabetic Kidney Disease. de Vos LC; Hettige TS; Cooper ME Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579 [TBL] [Abstract][Full Text] [Related]
35. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database. Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099 [TBL] [Abstract][Full Text] [Related]
36. Determining When to Recommend Glucose-Lowering Drugs That Reduce Cardiovascular Risk. Robertson S Am Fam Physician; 2022 Jan; 105(1):10-12. PubMed ID: 35029936 [No Abstract] [Full Text] [Related]
37. Evolving Concepts of Type 2 Diabetes Management. Abushamat LA; Reusch JEB Med Clin North Am; 2021 Nov; 105(6):955-966. PubMed ID: 34688420 [TBL] [Abstract][Full Text] [Related]
38. A review on cardiovascular effects of newer hypoglycaemic medications. Cutshall BT; Twilla JD; Olinger AS; Oliphant CS Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743 [TBL] [Abstract][Full Text] [Related]
39. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study. Jermendy G; Kiss Z; Rokszin G; Abonyi-Tóth Z; Wittmann I; Kempler P Diabetes Ther; 2018 Oct; 9(5):2133-2141. PubMed ID: 30120754 [TBL] [Abstract][Full Text] [Related]
40. Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments. Iwakura K J Echocardiogr; 2019 Dec; 17(4):177-186. PubMed ID: 31617144 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]